MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Incyte Corp

Slēgts

SektorsVeselības aprūpe

67.8 -1.58

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

67.69

Max

68.94

Galvenie mērījumi

By Trading Economics

Ienākumi

-43M

158M

Pārdošana

-126M

1.1B

P/E

Sektora vidējais

349.9

39.857

EPS

1.16

Peļņas marža

15.025

Darbinieki

2,617

EBITDA

-80M

257M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+14.98% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 29. jūl.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-2.5B

14B

Iepriekšējā atvēršanas cena

69.38

Iepriekšējā slēgšanas cena

67.8

Ziņu noskaņojums

By Acuity

41%

59%

150 / 376 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

Incyte Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 17. jūl. 23:34 UTC

Iegādes, apvienošanās, pārņemšana

FTC Reopens Consent Orders for Proposed Acquisitions from Exxon Mobil, Chevron

2025. g. 17. jūl. 21:14 UTC

Iegādes, apvienošanās, pārņemšana

Basel Medical Group Puts $1 Billion Bitcoin Purchase on Hold

2025. g. 17. jūl. 21:04 UTC

Galvenie tirgus virzītāji
Iegādes, apvienošanās, pārņemšana

Norfolk Southern Shares Rise on WSJ Report of Union Pacific Acquisition Interest

2025. g. 17. jūl. 23:43 UTC

Tirgus saruna

Gold Edges Higher on Possible Position Adjustments -- Market Talk

2025. g. 17. jūl. 23:42 UTC

Tirgus saruna

Nikkei May Rise on Signs of U.S. Econ Strength -- Market Talk

2025. g. 17. jūl. 22:47 UTC

Iegādes, apvienošanās, pārņemšana

FTC: Maintaining Restrictions for Former Pioneer CEO Scott Sheffield Would Damage FTC's Credibility

2025. g. 17. jūl. 22:46 UTC

Iegādes, apvienošanās, pārņemšana

Potential Rail Merger Could Prompt Berkshire Hathaway to Bid for CSX -- Barrons.com

2025. g. 17. jūl. 22:46 UTC

Iegādes, apvienošanās, pārņemšana

FTC Also Says Exxon Order Disregarded Guidelines and Precedent

2025. g. 17. jūl. 22:43 UTC

Iegādes, apvienošanās, pārņemšana

FTC: Maintaining Restrictions on John Hess's Employment Would 'Damage the FTC's Credibility'

2025. g. 17. jūl. 22:43 UTC

Iegādes, apvienošanās, pārņemšana

FTC: Chevron Order Disregarded FTC Merger Guidelines and Decades of Precedent

2025. g. 17. jūl. 22:40 UTC

Iegādes, apvienošanās, pārņemšana

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

2025. g. 17. jūl. 22:40 UTC

Iegādes, apvienošanās, pārņemšana

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

2025. g. 17. jūl. 22:30 UTC

Tirgus saruna
Peļņas

Netflix Sticks to Its Playbook as Competitive Landscape Changes -- Market Talk

2025. g. 17. jūl. 22:20 UTC

Tirgus saruna
Peļņas

Global Equities Roundup: Market Talk

2025. g. 17. jūl. 22:20 UTC

Tirgus saruna
Peļņas

Netflix Focusing Resources on TV Viewers It Hasn't Yet Captured -- Market Talk

2025. g. 17. jūl. 22:04 UTC

Tirgus saruna
Peļņas

Netflix Redesign Done to Match Current Capabilities -- Market Talk

2025. g. 17. jūl. 22:03 UTC

Iegādes, apvienošanās, pārņemšana

China Threatens to Block Panama Ports Deal Unless Its Shipping Giant Is Part of It -- 2nd Update

2025. g. 17. jūl. 21:58 UTC

Tirgus saruna
Peļņas

Netflix Internal Data Doesn't Indicate Weaker Consumer Sentiment -- Market Talk

2025. g. 17. jūl. 21:57 UTC

Peļņas

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

2025. g. 17. jūl. 21:47 UTC

Peļņas

Netflix Raises Revenue, Margin Forecasts After Strong Second Quarter -- Update

2025. g. 17. jūl. 21:45 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 17. jūl. 21:45 UTC

Tirgus saruna

Crypto Bills Welcomed by Venture Capital, Trade Group Says -- Market Talk

2025. g. 17. jūl. 21:38 UTC

Iegādes, apvienošanās, pārņemšana

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- 2nd Update

2025. g. 17. jūl. 21:22 UTC

Iegādes, apvienošanās, pārņemšana

Update: Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

2025. g. 17. jūl. 21:05 UTC

Peļņas

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

2025. g. 17. jūl. 21:04 UTC

Iegādes, apvienošanās, pārņemšana

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- Update

2025. g. 17. jūl. 21:02 UTC

Iegādes, apvienošanās, pārņemšana

Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

2025. g. 17. jūl. 20:59 UTC

Iegādes, apvienošanās, pārņemšana

Basel Medical Group Puts $1B Bitcoin Purchase on Hold

2025. g. 17. jūl. 20:50 UTC

Tirgus saruna
Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 17. jūl. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Incyte Corp Prognoze

Cenas mērķis

By TipRanks

14.98% augšup

Prognoze 12 mēnešiem

Vidējais 79.6 USD  14.98%

Augstākais 107 USD

Zemākais 52 USD

Pamatojoties uz 17 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Incyte Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

17 ratings

7

Pirkt

9

Turēt

1

Pārdot

Tehniskais rādītājs

By Trading Central

59.52 / 62.66Atbalsts un pretestība

Īstermiņā

Bullish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Bearish Evidence

Noskaņojums

By Acuity

150 / 376 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation